

1 **Metabolite analysis of *Mycobacterium* species under aerobic and**
2 **hypoxic conditions reveals common metabolic traits**

3

4 **Margit Drapal¹, Paul R. Wheeler² and Paul D. Fraser^{1*}**

5

6 ¹School of Biological Sciences, Royal Holloway University of London, Egham, U.K.

7 ²Tuberculosis Research Group, Veterinary Laboratories Agency Weybridge, New Haw, U.K.

8

9 *Correspondence: Tel.: 01784-443894, Fax.: 01784-4434326, E-mail: P.Fraser@rhul.ac.uk.

10

11 Running title: Metabolic profiling of *Mycobacterium* species

12

13 Keywords: *Mycobacterium* spp., metabolomics, non-replicating persistence, lipid secretion

14

15 Abbreviations: ACAT, acyl-CoA acetyltransferase; BCG, Bacillus Calmette-Guerin; cfu, colony forming
16 units; DGAT, diacylglycerol O-acyltransferase; ESAT, early secretory antigen target; GC, gas
17 chromatography; LC, liquid chromatography; MK9, menaquinone with nine isoprenoid side chain
18 residues; MS, mass spectrometry; Mtb, *Mycobacterium tuberculosis*; NRP, non-replicating persistence;
19 OD, optical density; TAG, triacylglycerides; TCA, tricarboxylic acid; TDM, trehalose dimycolate; TMM,
20 trehalose monomycolate.

21

22 Number of words in abstract: 261

23 Number of words in main text: 4708

24

25 **Abstract (250 words)**

26 A metabolite profiling approach has been implemented to elucidate metabolic adaptation at set culture
27 conditions in five Mycobacterium species with the potential to act as model organisms for
28 Mycobacterium tuberculosis (Mtb). Analysis has been performed over designated growth phases and
29 under representative environments (nutrient and oxygen depletion) experienced by Mtb during infection.
30 The procedure was able to determine a range of metabolites (60 - 120 compounds) covering
31 nucleotides, amino acids, organic acids, saccharides, fatty acids, glycerols, -esters, -phosphates and
32 isoprenoids. Among these classes of compounds key biomarker metabolites were identified that can
33 act as indicators of pathway/process activity. In numerous cases, common metabolite traits were
34 observed for all five species across the experimental conditions. Amino acid content, especially glutamic
35 acid, highlighted the different properties between the fast- and slow-growing mycobacteria studied. The
36 greatest similarities in metabolite composition between fast- and slow-growing mycobacteria were
37 apparent under hypoxic conditions. A comparison to previously reported transcriptomic data revealed
38 a strong correlation between changes in transcription and metabolite content. Collectively, these data
39 validate the changes in the transcription at the metabolite level, suggesting transcription exists as one
40 of the predominant modes of cellular regulation in Mycobacterium. Whilst, sectors with restricted
41 correlation between metabolites and transcription (e.g. hypoxic cultivation) warrant further study to
42 elucidate and exploit post-transcriptional modes of regulation. The strong correlation between the
43 laboratory conditions used and data derived from in vivo conditions, indicates that the approach applied
44 is a valuable addition to our understanding of cell regulation in these Mycobacterium species.

45 Introduction

46 The genus *Mycobacterium* contains a variety of species with different phenotypes (e.g. fast- and slow-
47 growers, chromogens, pathogens and saprophytes) and hence, provides a range of suitable model
48 organisms for Mtb. The suitability of *Mycobacterium* species as model organisms has been extensively
49 discussed highlighting differences/similarities in growth rate, cell envelope chemistry,
50 pathogenicity/biosafety and their phylogenetic relationship compared to Mtb (e.g. Barry, 2001). For the
51 purpose of this study, two fast-growing (*M. smegmatis* and *M. phlei*) and three slow-growing (*M. bovis*
52 BCG, *M. avium* and *M. intracellulare*) mycobacteria were chosen to represent a diverse range of
53 *Mycobacterium* species. These mycobacteria were analysed at set growth stages to show adaptation
54 processes upon the induction of abiotic stresses (e.g. nutrient and oxygen limitation through natural
55 depletion of given resources) which are comparable to the microenvironment experienced by Mtb. The
56 metabolite levels monitored elucidated metabolic pathways common to the genus *Mycobacterium* (e.g.
57 mycolic acid synthesis (Gago *et al.*, 2011)) and specific to certain phenotypes mentioned above (e.g.
58 poly-glutamine synthesis in slow-growers (Harth and Horwitz, 1999)).

59 The culture conditions in the present study were based on published *in vitro* models (Wayne and Hayes,
60 1996) to represent typical environments experienced by Mtb under physiological conditions. The
61 prevalent stress conditions experienced within the host, including infection stages of active replication
62 in alveolar macrophages and dormancy within granulomas (Chao and Rubin, 2010), involve a gradual
63 depletion of oxygen and nutrients (Russell *et al.*, 2010). To minimise environmental influences on the
64 mycobacterial cells, they were cultivated in a standardised volume of nutrient rich medium with no
65 additionally supplementation over the duration of the experiments creating a natural depletion of
66 nutrients over the period of batch cultivation. The three culture conditions investigated included growth
67 from lag to stationary phase (Phase I) and growth from logarithmic (log) phase for 28d under aerated
68 (Phase II) or hypoxic (Phase III) conditions. To capture the changes in metabolites occurring under
69 these conditions a quantitative metabolite profiling approach was used (Drapal *et al.*, 2014). The
70 resulting changes at the metabolite level were compared with previous published transcriptomic and
71 proteomic data (e.g. (Betts *et al.*, 2002; Hampshire *et al.*, 2004)) for a better understanding of cellular
72 regulation in *Mycobacterium* and its changing chemotype with environmental adaptation. Collectively,
73 these data will enable an assessment of how representative the laboratory conditions used are
74 compared to real life scenarios.

75

76 **Material and Methods**

77 **Bacteria**

78 *M. smegmatis* (National Collection of Type Cultures (NCTC) 8159, Public Health England,), *M. phlei*
79 (NCTC 8151), *M. bovis* BCG (Pasteur strain, from AHVLA Collection, Weybridge, UK), *M. avium*
80 (serotype 8, private collection) and *M. intracellulare* (serotype 7, private collection) were cultivated and
81 prepared as a starting culture as published previously (Drapal *et al.*, 2014). For the following culture
82 conditions five replicates per species were grown in parallel.

83 For Phase I cultivation, fresh Middlebrook 7H9 supplemented with 10% OADC (oxalic acid,-albumin-
84 dextrose-catalase) and 0.4% Tween 80 was inoculated with the starting culture until an initial optical
85 density at 600nm (OD) of 0.1 or 0.05, for fast- and slow-growing mycobacteria respectively, was
86 reached. The cultures (1.5 times the total volume sampled) were then incubated shaking (180 rpm,
87 37°C) under aerated conditions in vent-cap flasks.

88 For the other two culture conditions, fresh medium (1.5 times the total volume sampled) was inoculated
89 as described for Phase I and incubated shaking (180 rpm, 37°C) under constant aeration in vent-cap
90 flasks. After 16h (*M. smegmatis*), 1d (*M. phlei*) or 7d (*M. bovis* BCG, *M. avium*, *M. intracellulare*) an
91 aliquot (8 ml) of the inoculated medium was sampled representing the induction point of the two different
92 oxygen conditions. The aerated, shaking condition was maintained for Phase II cultivation and samples
93 (8 ml) were taken at 1d, 2d and 28d after induction for all mycobacteria. For the hypoxic cultivation
94 (Phase III), the cultures were aliquoted (8 ml) at the induction point and all aliquots cultivated without
95 stirring at 37°C until sampled for analysis. The depletion of oxygen in the hypoxic culture was visualised
96 by discolouration of methylene blue (1.5 µg/ml cell culture). Aliquots of inoculated medium (8 ml) were
97 sampled following the same time regime as described for Phase II.

98 **Sampling and analysis of polar and non-polar metabolites**

99 Aliquots of the cultures were quenched with isotonic 60% (v/v) methanol, centrifuged and the resulting
100 cell pellet weighed. The cells were the extracted with a methanol/chloroform method followed by
101 analysis with gas chromatography mass spectrometry (GC/MS) and high performance liquid
102 chromatography (HPLC) as previously published (Drapal *et al.*, 2014). The metabolites of each sample
103 were identified through a customized library (Drapal *et al.*, 2014). Variation in the number and type of
104 metabolites identified occurred at each sampling point. The GC/MS results were normalised to the
105 internal standard and weight of the cell pellet. The identified compounds within each culture condition
106 were compared to the first time point taken. Statistically significant changes of metabolites were
107 analysed with one-way ANOVA with Dunnett's post-test and were then plotted over a pathway diagram.

108 **Identification of lipids and proteins of the secreted layer**

109 After four days of induction of hypoxia, the secreted layer was carefully removed from the cell pellet and
110 separately analysed for lipid and protein content. For the identification of lipids, the collected secreted
111 layer was dissolved (1:2) in chloroform/methanol/water (10:10:3, v/v/v). The diluted sample was then
112 mixed (1:1) with 2,5-dihydroxybenzoic acid matrix (5 mg/ml in acetonitrile with 0.1% (v/v) trifluoroacetic

113 acid) and placed on a 600 µm Anchor chip 384 format MALDI target plate (Bruker Daltonics) before
114 analysis with MALDI–TOF/TOF-MS as described previously (Jones *et al.*, 2013).

115 For the identification of proteins of the secreted layer, a previously published protocol (Robertson *et al.*,
116 2012; Mora *et al.*, 2013) was followed which included precipitation of proteins and separation by SDS-
117 PAGE followed by in-gel digestion of the four major protein bands and analysis with nano-LC/MS/MS.
118 The proteins were identified through the detected peptides as previously published (Nogueira *et al.*,
119 2013) with SwissProt protein database for taxonomy *M. tuberculosis* complex.

120

121 Results

122 Growth properties under aerated and hypoxic cultivation

123 The growth curves for all three culture conditions were measured by monitoring optical density (OD)
124 and colony forming units (cfu) (Supplementary File 1). Both these measurements over Phase I showed
125 the typical sigmoid shape for all five mycobacteria (Fig. 1). The culture condition Phase II was
126 characterised by an almost horizontal linear curve at at least 2d after log phase. Again all five
127 mycobacteria showed similar growth properties (Fig. 1). The OD data was consistent with the cfu
128 measurements and indicated a constant viable count of culturable cells which is associated with data
129 found for non-replicating persistence (NRP) 1 (Chao and Rubin, 2010; Shi *et al.*, 2010; Bacon *et al.*,
130 2014). The exception was *M. phlei* which showed a decline of growth from 1d to 2d after the log phase
131 followed by constant values until 28d suggesting a death phase before the switch to NRP (Bacon *et al.*,
132 2014). Interestingly, a resurgent increase of cfu values was detected at 28d (Phase II) only for *M.*
133 *smegmatis*, *M. avium* and *M. intracellulare* which indicated a reactivation of cells or a second log phase
134 of the remaining active cells. Phase III cultures, contrary to Phase II, showed an immediate stop of
135 replication at the first time point after induction of hypoxic conditions conferred by the removing of
136 agitation (Fig. 1). This was shown through constant values similar to the induction point (log phase)
137 measured until 28d and would indicate that the cells are capable of rapid detection/adaptation to the
138 change in oxygen concentration. This change in condition was monitored *in situ* by the reduction of
139 methylene blue in the medium. Discolouration arose four hours after induction, which was approximately
140 half the duration required for all cells to settle at the bottom of the culture tube and was the same for all
141 five mycobacteria. All samples retained the discolouration throughout Phase III.

142 The metabolite profile was measured at each set time point and compared to the first time point of the
143 culture condition for each *Mycobacterium* species separately. The resulting changes of metabolite
144 levels were calculated and their significance evaluated (Supplementary File 2). Key metabolites within
145 the data set were chosen to visualise changes of nucleotides, the nitrogen and sulphur pathways, TCA
146 cycle, glyoxylate shunt, the biosynthesis of fatty acids and complex lipids and thus describe the
147 metabolic state over the growth stages.

148 Metabolite changes occurring at the logarithmic and stationary growth phases (Phase I)

149 Overall ~70 compounds were detected throughout Phase I for four of the five mycobacteria tested. *M.*
150 *phlei* was the exception with 126 metabolites detected. The summarised Phase I data for all five
151 mycobacteria (Fig. 2) highlighted the differences in metabolite levels between the fast-growing and the
152 slow-growing *Mycobacterium* species. Interestingly, the slow-growers had decreased metabolite levels
153 predominantly, when compared to lag phase, which suggested that metabolites associated with primary
154 metabolism were not detectable or rapid utilisation occurred. The data on the fast-growers, *M. phlei* and
155 *M. smegmatis*, showed increased levels of polar metabolites suggesting accumulation of the latter. *M.*
156 *bovis* BCG, being one of the slow-growing mycobacteria, showed similar metabolite changes to *M.*
157 *avium* and *M. intracellulare* but differed from the latter two as more metabolites were detected in *M.*
158 *bovis* BCG including uracil, glycine, fatty acid precursors and intermediates of the TCA cycle.

159 The common nucleotide detected in *M. smegmatis*, *M. bovis* BCG and *M. phlei* was uracil and showed
160 increased levels from log phase onwards. *M. phlei* had the most nucleotides detected which showed
161 the same increasing trends as uracil (Supplementary File 2). No nucleotides were detected for *M. avium*
162 and *M. intracellulare* over Phase I which would be compliant with rapid utilisation.

163 Homocysteine, the key intermediate of the sulphur pathway, can be metabolised via cysteine to
164 mycothiol (Zeng *et al.*, 2013) or converted to methionine (Singhal *et al.*, 2013) leading to reduced levels
165 of the latter as detected throughout Phase I, in four out of five mycobacteria tested. *M. phlei* was the
166 only *Mycobacterium* species in this study for which no homocysteine but increased cysteine levels were
167 detected.

168 Glutamic acid, the preferred nitrogen assimilation product (Amon *et al.*, 2009), showed higher levels at
169 log compared to the stationary phase in *M. phlei* and *M. smegmatis*. *M. intracellulare* was the only slow-
170 growing species which showed up-regulation of glutamic acid at stationary phase. The other two slow-
171 growing species, *M. bovis* BCG and *M. avium*, had decreased levels of glutamic acid. Additionally, in
172 *M. bovis* BCG levels of proline were increased.

173 The only intermediate of the TCA cycle which was detected in all five mycobacteria studied throughout
174 Phase I was succinic acid. This intermediary metabolite connects the TCA cycle, glyoxylate shunt and
175 methylcitrate cycle, which are all involved in fatty acid synthesis and catabolism (Eoh and Rhee, 2013).
176 Succinic acid and odd-chain fatty acids were decreased in the three slow-growing mycobacteria studied.
177 In the case of *M. phlei* and *M. smegmatis*, levels of succinic acid showed no change or an increase at
178 log phase, respectively. For glyoxylate, the key intermediate of the glyoxylate shunt, the derivative
179 glycolate was detected by GC/MS, due to chemical structures created during derivatisation process.
180 Glycolate was down-regulated throughout Phase I in all mycobacteria studied, except *M. smegmatis* for
181 which no glyoxylate was detected. Additionally, malonic acid, the dicarboxylic acid of malonyl-CoA, was
182 detected and its levels increased at the stationary phase for *M. bovis* BCG and *M. smegmatis* and at
183 the log phase of *M. phlei*. The even-chain fatty acids, consecutive intermediates of malonyl-CoA and
184 precursors for biosynthesis of mycolic acids (Crellin *et al.*, 2013), were reduced in all five mycobacteria
185 studied throughout Phase I. Similarly, the content of glycerol, utilised for glycerol- and phospholipid
186 biosynthesis (Crellin *et al.*, 2013), was decreased or at levels below the limit of detection. Besides
187 malonic acid, fatty acid precursors isoleucine, threonine, leucine and valine were detected with
188 increased levels for *M. bovis* BCG, *M. smegmatis* and *M. phlei*.

189 Saccharides associated with components of the cell wall (arabinose, galactose, inositol, mannose and
190 trehalose) showed different trends in all mycobacteria tested over Phase I. Arabinose, part of the
191 arabinogalactan, was only detected in *M. smegmatis* at stationary phase. Galactose, also part of the
192 arabinogalactan, was decreased in all mycobacteria except *M. phlei* which showed increased levels at
193 log and no change at the stationary phase. Contrary to this, inositol and mannose-6-phosphate, both
194 components of plasma membrane related lipids, were increased in all mycobacteria except *M. avium*,
195 which showed decreased levels throughout Phase I. Trehalose, the backbone of trehalose mono- and
196 dimycolates (TMM, TDM), showed the most differences in contents between the five mycobacteria
197 tested. It was increased throughout Phase I for *M. smegmatis*, at log phase for *M. phlei*, at stationary

198 phase for *M. intracellulare* and showed no change and decreased levels throughout in *M. avium* and
199 *M. bovis* BGC, respectively.

200 An essential metabolite for the electron transport chain is menaquinone (MK) 9, the major lipoquinone
201 in *Mycobacterium* species (Mathew *et al.*, 2010). It was detected with overall decreased contents
202 compared to lag phase in all mycobacteria studied and showed increasing levels between log and
203 stationary phase for all species except for *M. phlei*. The data for *M. phlei* showed further decrease of
204 MK9 from log to stationary phase and increased levels of β -carotene throughout Phase I. *M.*
205 *intracellulare*, the other chromogenic *Mycobacterium* species studied, produced only phytoene, a
206 colourless carotenoid which represent the first step in the C40 pathway, during Phase I. Metabolite
207 profiling features found over Phase I, such as even-chain fatty acid and glycerol metabolism and MK9
208 levels, highlighted similarities between the mycobacteria studied.

209

210 **Metabolic changes under elongated aerated cultivation (Phase II)**

211 In all five mycobacteria, more compounds were detected over Phase II compared to Phase I. *M. phlei*
212 had the most metabolite changes measured over Phase II which were mainly lower levels compared to
213 the initial time point of measurement (Fig. 3).

214 Nucleotide metabolism appeared to be active in all five mycobacteria as a variety of changes in
215 nucleotide constituents were detected throughout Phase II. Amino acid content was unchanged for *M.*
216 *avium* and *M. intracellulare* at 1d and 2d, respectively, and decreased for *M. phlei*. Contrary to this, *M.*
217 *smegmatis* and *M. bovis* BCG showed an increase in number and levels of amino acids especially at
218 2d of Phase II.

219

220 Even though the overall trends of amino acid levels differed between the five mycobacteria studied, the
221 amino acids involved in the sulphur and nitrogen pathways were similar between them.
222 Homocysteine/cysteine content showed no change overall and glutamic acid levels showed a
223 decreasing trend throughout Phase II after an initial increase for *M. smegmatis* and *M. intracellulare*.
224 Additionally, *M. phlei* had decreased levels of biochemically related consecutive intermediates of
225 glutamic acid (ornithine and citrulline), whereas *M. bovis* BCG and *M. smegmatis* showed increased
226 levels at 1d or 2d (proline and ornithine) (Supplementary File 2).

227 The glyoxylate shunt seemed activated after 1d for *M. smegmatis* and after 2d for BCG and *M. avium*
228 which was indicated by increased levels of glyoxylate and/or glycine. *M. intracellulare* showed
229 decreased levels of glyoxylate at 2d and no change of glycine. Whereas, *M. phlei* had decreased levels
230 of both glyoxylate and glycine throughout Phase II with a further decrease from 1d to 2d.

231 The metabolite profiling data of Phase II showed that trehalose and glycerol contents were related to
232 even chain fatty acid levels which are all precursors for the biosynthesis of TDM or triacylglyceride
233 (TAG). In *M. phlei*, fatty acids and trehalose were decreased, whereas in the three slow-growing species
234 no change was detected for both trehalose and fatty acids within the first two days of Phase II.
235 Furthermore, glycerol-3-phosphate was increased for *M. bovis* BCG and *M. intracellulare* and together

236 with glycerol-esters decreased in *M. avium* and *M. phlei*. Only *M. smegmatis* showed no change of fatty
237 acids, an increase in trehalose and a decrease of glycerol-3-phosphate.
238 The chromogenic mycobacteria (*M. phlei* and *M. intracellulare*) and *M. smegmatis* had increased levels
239 of isoprenoids throughout Phase II and increased levels of MK9 at 1d except for *M. phlei* which showed
240 no change in MK9 levels. *M. avium* and *M. bovis* BCG showed no change of MK9 and an additional MK
241 (MK8) was detected for *M. bovis* BCG.

242 Cultivation of mycobacteria tested over Phase II highlighted differences between the *Mycobacterium*
243 species, especially for *M. phlei* which showed down-regulated metabolite levels throughout Phase II
244 and even further decreases at 28d whereas the other mycobacteria showed a predominantly positive
245 metabolic switch at the last time point. At 28d, *M. smegmatis* showed increased levels of the glyoxylate
246 shunt, sulphur pathway and fatty acids and *M. bovis* BCG showed increased levels of the glyoxylate
247 shunt, nucleotides and fatty acid precursors indicating activated energy metabolism and induced activity
248 for cell replication. At the same time, *M. avium* and *M. intracellulare* showed a distinct metabolic
249 activation of all pathways with mainly increased levels except for glycerol-esters which were decreased.
250 For *M. smegmatis*, *M. avium* and *M. intracellulare* these metabolic changes at 28d were also reflected
251 with increased cfu values as described earlier.

252

253 **Effects of hypoxic culture conditions on metabolite levels (Phase III)**

254 Over Phase III, mycobacterial cells were not agitated and became oxygen-depleted, a well-documented
255 effect (Wayne and Sohaskey (2001)). The measured changes of metabolites over Phase III were more
256 similar between the five mycobacteria tested (Fig. 4) compared to the data described for Phase II. In
257 general, fewer metabolites were detected in Phase III (~90) than Phase II (~110).

258 The number of nucleotides detected followed this trend with a decrease in amount and number or a
259 general lack of nucleotides detected for *M. smegmatis*, *M. avium* and *M. intracellulare*, respectively. In
260 *M. bovis* BCG uracil showed increased levels after 2d and in *M. phlei* the highest number of nucleotides
261 was detected with increased levels of most nucleotides at 1d (Supplementary File 2).

262

263 No change of homocysteine levels was detected for *M. bovis* BCG throughout Phase III, for *M.*
264 *intracellulare* after 1d and for *M. smegmatis* and *M. avium* until 28d. All three mycobacteria had
265 increased levels of homocysteine at the other time points. As seen in Phase I and II, only cysteine was
266 detected in *M. phlei* with decreased levels throughout Phase III.

267 A striking observation was the decrease of glutamic acid in all three slow-growers throughout Phase III
268 whereas the fast-growing species showed increased levels. Only two biochemically related consecutive
269 metabolites, proline and ornithine, were detected in *M. smegmatis* and *M. phlei*, respectively, with
270 increased content at 1d.

271 The succinic acid levels varied for all five mycobacteria tested. *M. smegmatis* and *M. avium* showed
272 decreased levels from 1d and 2d, respectively, in *M. bovis* BCG no change occurred and *M. phlei* and
273 *M. intracellulare* showed increased followed by decreased levels of succinic acid at 1d and 2d,
274 respectively. Similar to succinic acid, precursors for lipid and cell wall synthesis (glycerol, fatty acids

275 and saccharides) were expressed with different metabolite levels for all mycobacteria. *M. smegmatis*
276 and *M. avium* showed decreased levels of glycerol-3-phosphate whereas *M. phlei* and *M. intracellulare*
277 showed increased levels of glycerol-3-phosphate and -esters, respectively, at 1d followed by no change
278 from 2d onwards. *M. bovis* BCG showed an increase of glycerol, -phosphate and -esters and most fatty
279 acids at 2d with the exception of decreased levels of C18:0 throughout Phase III, a fatty acid favoured
280 for first or second position of TAG (Walker *et al.*, 1970). Arabinose was detected in *M. smegmatis* at 1d
281 and in *M. phlei* and *M. avium* at 28d. Galactose content was mainly unchanged over Phase III apart
282 from decrease throughout in *M. smegmatis* and increase at 1d in *M. phlei*. At 1d *M. phlei* also had an
283 increased content of mannose which was otherwise unchanged for the other four species. Inositol and
284 trehalose were detected with similar trends of levels over Phase III. For *M. smegmatis* they were
285 increased over the first two days and at 2d, respectively. In *M. avium* both saccharides were decreased
286 after 1d and 2d, respectively. Inositol and trehalose were unchanged in *M. bovis* BCG until 28d at which
287 point they were decreased. *M. intracellulare* also showed unchanged levels of inositol and an increase
288 at 28d whereas trehalose was increased until 2d and showed no change at 28d. In *M. phlei*, trehalose
289 and inositol were increased at 1d followed by no change of trehalose and decreased levels of inositol.
290 MK9 levels showed no change over Phase III for all mycobacteria tested and for *M. intracellulare* after
291 1d. For *M. bovis* BCG MK8 and MK9 were detected as described for Phase II. A smaller number of
292 carotenoids (less than half) was detected for *M. phlei* and *M. intracellulare* over Phase III compared to
293 Phase II. The carotenoids showed no change except for phytoene which was increased throughout
294 Phase III.

295 At 28d of Phase III a renewed change of metabolite levels were detected similar to Phase II but without
296 an increase in cfu number. *M. bovis* BCG and *M. smegmatis* showed activation of sulphur and energy
297 metabolism (e.g. glyoxylate shunt, fatty acid metabolism) and an increase of nucleotide levels
298 (Supplementary File 2). *M. smegmatis* and *M. intracellulare* had increased contents of almost all fatty
299 acids detected. Furthermore, *M. avium* and *M. intracellulare* showed activity for all metabolic pathways
300 as described for Phase II with the exception of increased levels of nucleotides for *M. avium*.

301

302 The most striking property of the hypoxic cultivation was a secreted lipid layer of only the two fast-
303 growing *Mycobacterium* species (Fig. 5a). Three to four days after induction of hypoxic conditions, a
304 translucent layer became visible right above the cell pellet and showed a clear separation from the
305 medium. The control tube, containing bacterial-free medium, showed no such occurrence, indicating
306 that the layer was a product of the bacteria. In the case of the chromogenic *M. phlei*, the extracellular
307 material was coloured yellow/orange throughout and showed a zone of denser colouration at the border
308 to the cell pellet. Analysis of carotenoids extracted from the secretion did not show any results as the
309 amount of carotenoids was below the level of detection due to the volume of secretion per tube (~50
310 µl/10 mg cell pellet). Thus, the concentration of carotenoids could be significant but the total amount of
311 extracellular material precludes adequate extractable amounts.

312 After collection, the secreted layer was analysed for metabolite and protein composition. The analysis
313 with MALDI showed two series of peaks from 525 to 917 m/z and 1005 to 2035 m/z (Fig. 5b). The
314 fingerprint of the molecular ion peaks was typical for MALDI spectra of TAG as seen through

315 comparison with TAG spectra of *M. brumae* (Rafidinarivo *et al.*, 2009). The MALDI data suggested that
316 TAG was the main compound of the secretion as no other spectra were detected in the sample. The
317 two series of peaks in the TAG spectrum of *M. smegmatis* further indicated two different types of TAGs
318 due to a combination of fatty and mycolic acids with different chain length as described for *M. brumae*
319 (Rafidinarivo *et al.*, 2009).

320 For the protein analysis, proteins were extracted from the secreted layer and separated by SDS-PAGE.
321 The same pattern of protein bands was seen for both fast-growing mycobacteria. The two major protein
322 bands of both species were identified as a putative diacylglycerol O-acyltransferase (DGAT, ~63 kDa)
323 from *Mycobacterium* and acyl-CoA acetyltransferase (ACAT, ~40 kDa). Furthermore, a match for the
324 early secreted antigen target (ESAT)-6-like protein EsxB (~11kDa) was found.

325

326

327 **Discussion**

328 The metabolome, as the end product of gene expression and protein regulation (Harrigan and
329 Goodacre, 2003; Boshoff and Lun, 2010), can be used to give a mechanistic insight into adaptation
330 processes of an organism. An example in the present study is increasing levels of uracil detected
331 through all culture conditions as part of DNA repair of G+C rich bacteria in macrophage infections
332 (Venkatesh *et al.*, 2003; Cossu *et al.*, 2012). Difficulties of metabolite profiling methods, including the
333 quick metabolic turn-over and leakage during sampling, were minimised in the approach used (Drupal
334 *et al.*, 2014) and results reveal snapshots of the intracellular metabolism. Furthermore, the comparison
335 of the metabolic data with transcriptional and translational data elucidates the principal mode of cellular
336 regulation during adaptation to a stress condition.

337 The identified common properties of all mycobacteria specific to a culture condition (Fig. 6) were
338 consistent with transcriptional and translational data published (e.g. during macrophage infection
339 (Sasseti and Rubin, 2003)). For Phase I this included an active nucleotide and amino acid metabolism
340 (Wang *et al.*, 2005) which ceased with cell replication over Phase III as reported under *in vivo* and *in*
341 *vitro* conditions (Wayne and Sohaskey, 2001; Betts *et al.*, 2002). Additionally, changes in homocysteine
342 levels as precursor for cell wall maintenance (Dhiman *et al.*, 2009) and for protein and nucleotide
343 synthesis (Singhal *et al.*, 2013) were detected. MK9 and isoprenoids, both involved in the electron
344 transport chain, seemed to play an essential interconnected role over all three conditions tested (Lee
345 *et al.*, 2008; Dhiman *et al.*, 2009). Another important and already well known compound class for
346 mycobacteria are lipids which act as a barrier to the environment (e.g. TDM) (Archuleta *et al.*, 2005)
347 and as carbon/energy storage (e.g. TAG) (Crellin *et al.*, 2013). Their precursor metabolites detected
348 included fatty acids, monosaccharides and glycerol derivatives. All of these metabolites displayed an
349 active metabolism during replication cycles for plasma membrane and cell wall (Sasseti *et al.*, 2003;
350 Crellin *et al.*, 2013) as well as part of the adaptation to environmental changes (Archuleta *et al.*, 2005)
351 and the transition to the dormant state in Mtb as reported in mycobacterial infections (Stehr *et al.*, 2013).

352 One typical mycobacterial feature is the redirection of the carbon flow under reduced oxygen conditions
353 which results in a switch of the TCA cycle to the glyoxylate shunt (Sasseti and Rubin, 2003; Eoh and
354 Rhee, 2013). Succinic acid and glyoxylate, both products of the isocitrate lyase in the glyoxylate shunt
355 (Eoh and Rhee, 2013), were detected in this study. The detection of both of those metabolites over
356 Phase I suggested that the glyoxylate shunt was already activated during active replication contrary to
357 published literature (e.g. Wayne and Sohaskey, 2001; Chao and Rubin, 2010). Levels of glyoxylate and
358 related metabolites indicated a far less active glyoxylate shunt over Phase II than that described for a
359 transcriptomic study following progressive nutrient depletion similar to the conditions in the present
360 study (Hampshire *et al.*, 2004).

361 The main metabolic changes, which showed distinct differences between fast- and slow-growing
362 mycobacteria, were glutamic acid levels and sequestration of TAG over Phase III. Increased levels of
363 glutamic acid in the fast-growing species over Phase I were coherent with nitrogen assimilation under
364 nitrogen excess in the medium (Amon *et al.*, 2009) and suggests that fast-growing species can sense
365 upcoming limitation in the surrounding medium and adapt accordingly (Smeulders *et al.*, 1999).
366 Contrary to this, glutamic acid levels over Phase I in the slow-growing species were consistent with
367 utilisation of the latter for nucleotide and protein synthesis and transcriptional data for optimal growth

368 (Sasseti *et al.*, 2003). Over Phase III the lack of nucleotides in combination with decreased levels of
369 glutamic acid in slow-growing species suggested secretion of glutamic acid into the extracellular
370 environment. Pathogenic mycobacteria (e.g. *M. bovis* and *M. tuberculosis*) are known to release
371 glutamine synthetase during infection and synthesise poly-L-glutamate/glutamine as an extracellular
372 carbon and nitrogen storage (Harth and Horwitz, 1999). The intracellular accumulation of glutamic acid
373 for non-pathogenic mycobacteria (e.g. *M. phlei* and *M. smegmatis*) supports the hypothesis that
374 glutamic acid secretion is a trait of pathogenic mycobacteria.

375 For fast-growing species a release of TAG into the medium was observed a few days after Phase III
376 induction (Fig. 5). Lipid body formation with TAG is a common property of mycobacteria during the
377 hypoxic phase of the infection (e.g. Garton *et al.*, 2002; Low *et al.*, 2009) and *M. smegmatis* is known
378 to constantly releasing fatty acids or TAG into the medium (Selishcheva *et al.*, 2012). The proteins
379 detected in the secreted layer suggest simultaneous synthesis of TAG by DGAT similar to mycobacterial
380 infections (Stehr *et al.*, 2013) and β -oxidation of fatty acids by ACAT for butyryl-CoA and acetyl-CoA
381 synthesis (Kanehisa *et al.*, 2006). DGAT was detected in higher amounts than ACAT, resulting in more
382 TAG synthesis compared to β -oxidation and consequently the visible TAG layer. Saprophytic
383 mycobacteria usually cannot gain access to lipids originated from a host such as pathogenic
384 mycobacteria (Russell *et al.*, 2010). In the present study, oleic acid was available in the medium in its
385 free form and through hydrolysis of Tween 80. Hence, the production and secretion of TAG with oleic
386 acid might be the adaptation process of choice for non-pathogenic mycobacteria to create an
387 environment similar to foamy macrophages during infection with Mtb (Stehr *et al.*, 2013) and secure
388 storage of extracellular signalling metabolites (oleic acid) for resuscitation (Selishcheva *et al.*, 2012).
389 Similar metabolic changes related to TAG synthesis were detected over Phase II and highlight that TAG
390 synthesis and secretion might be a reaction to stressful conditions including nutrients and/or oxygen
391 depletion, leading to a NRP state (Wayne and Sohaskey, 2001). The metabolic changes related to
392 phenotypes suggests a possible genetic variation between pathogenic and non-pathogenic
393 mycobacteria due to necessities presented by their respective ecological niches.

394 In the present study a renewed increase in metabolic activity and growth rate was detected at 28d of
395 Phase II and III cultivation for all mycobacteria tested. The metabolic activities correlated with gene
396 expression for optimal growth over Phase I (Sasseti *et al.*, 2003), which indicates the presence of active
397 and “dormant” cells in the culture. This supports reports of heterogeneous culture in *in vivo* and *in vitro*
398 studies and suggested that this phenomenon is a mycobacterial trait and might provide new insight into
399 NRP cultures (Smeulders *et al.*, 1999; Chao and Rubin, 2010).

400 Despite the metabolic differences of non-pathogenic and pathogenic mycobacteria, a comparison of
401 their metabolic features provided valuable insight to *in vivo* studies as metabolic reactions detected
402 were consistent with results described for mycobacteria under macrophage infection. The present study
403 revealed that all *Mycobacterium* species maintain an active turn-over of metabolites involved in
404 transcription, translation and other general cellular processes through all three culture conditions. The
405 comparison with published literature highlighted that metabolic changes over a gradually occurring
406 nutrient depletion (Phase I and II) seemed to be more influenced by transcriptional and translational
407 processes, whereas cells experiencing a sudden oxygen reduction (Phase III) showed a more
408 independent metabolic regulation related to a phenotype. This suggested a more complex and diverse
409 regulation of intracellular processes over Phase III for the different phenotypes, contrary to the orderly

410 shift-down previously described (Cunningham and Spreadbury, 1998). This observation emphasises
411 the importance of integrated data from several levels of cellular regulation to guarantee sufficient data
412 for a more complex understanding of the biological processes as a whole.

413 In conclusion, all five *Mycobacterium* species can be considered as model organisms for Mtb in relation
414 to cell wall and MK9 synthesis over the cultures conditions tested. Whereas, most other metabolic
415 changes detected over the three culture conditions (e.g. poly-L-glutamate layer over Phase III) showed
416 a divide between fast- and slow-growing mycobacteria. This suggested that for metabolite profiling
417 study purposes *Mycobacterium* species phenotypically closer related to Mtb (e.g. *M. bovis* BCG and *M.*
418 *avium*) should be recommended as model organism. Given that a chloroform/methanol/water step,
419 lethal to mycobacteria, is used for the extraction of metabolites, the methodology is applicable to use
420 with ACDP3 pathogens such as virulent Mtb. The strong correlation between responses detected in the
421 present laboratory based study and published data, often acquired under conditions approaching *in*
422 *vivo* scenarios, adds support to the metabolomic approach as a means of obtaining conclusive datasets
423 for interpretation into exploitable networks. Thus, a metabolite profiling of at least one Mtb strain should
424 be done to further validate the presented conclusions and lead to a more precise consideration for the
425 choice of model species for metabolic modelling.

426

427

428 **Acknowledgements**

429 This work was supported by a Royal Holloway University of London studentship to PDF and Animal
430 Health and Veterinary Laboratories Agency, UK to PRW and the EUFP7 Colorspore project (PDF). We
431 thank Christopher Gerrish for technical support and guidance.

432

433 **REFERENCES**

- 434 **Amon, J., Titgemeyer, F., and Burkovski, A. (2009).** A genomic view on nitrogen metabolism and
435 nitrogen control in mycobacteria. *J Mol Microbiol Biotechnol* **17**, 20-29.
- 436 **Archuleta, R.J., Yvonne Hoppes, P., and Primm, T.P. (2005).** Mycobacterium avium enters a state of
437 metabolic dormancy in response to starvation. *Tuberculosis* **85**, 147-158.
- 438 **Bacon, J., Alderwick, L.J., Allnutt, J.A., Gabasova, E., Watson, R., Hatch, K.A., Clark, S.O., Jeeves,
439 R.E., Marriott, A., Rayner, E., Tolley, H., Pearson, G., Hall, G., Besra, G.S., Wernisch, L.,
440 Williams, A., and Marsh, P.D. (2014).** Non-replicating Mycobacterium tuberculosis elicits a
441 reduced infectivity profile with corresponding modifications to the cell wall and extracellular
442 matrix. *PLoS One* **9**, e87329.
- 443 **Barry, I.I.I.C.E. (2001).** Mycobacterium smegmatis: an absurd model for tuberculosis? *Trends*
444 *Microbiol* **9**, 473-474.
- 445 **Betts, J.C., Lukey, P.T., Robb, L.C., McAdam, R.A., and Duncan, K. (2002).** Evaluation of a nutrient
446 starvation model of Mycobacterium tuberculosis persistence by gene and protein expression
447 profiling. *Mol Microbiol* **43**, 717-731.
- 448 **Boshoff, H.I., and Lun, D.S. (2010).** Systems biology approaches to understanding mycobacterial
449 survival mechanisms. *Drug Discov Today Dis Mech* **7**, e75-e82.
- 450 **Chao, M.C., and Rubin, E.J. (2010).** Letting sleeping dogs lie: does dormancy play a role in
451 tuberculosis? *Annual review of microbiology* **64**, 293-311.
- 452 **Cossu, A., Sechi, L.A., Zanetti, S., and Rosu, V. (2012).** Gene expression profiling of Mycobacterium
453 avium subsp. paratuberculosis in simulated multi-stress conditions and within THP-1 cells
454 reveals a new kind of interactive intramacrophage behaviour. *BMC Microbiol* **12**, 87.
- 455 **Crellin, P.K., Luo, C.-Y., and Morita, Y.S. (2013).** Metabolism of Plasma Membrane Lipids in
456 Mycobacteria and Corynebacteria. In *Lipid Metabolism*, Vol., p. ^pp. 119 - 148, Edited by
457 Baez, P.R.V.
- 458 **Cunningham, A.F., and Spreadbury, C.L. (1998).** Mycobacterial stationary phase induced by low
459 oxygen tension: cell wall thickening and localization of the 16-kilodalton alpha-crystallin
460 homolog. *Journal of bacteriology* **180**, 801-808.
- 461 **Dhiman, R.K., Mahapatra, S., Slayden, R.A., Boyne, M.E., Lenaerts, A., Hinshaw, J.C., Angala, S.K.,
462 Chatterjee, D., Biswas, K., Narayanasamy, P., Kurosu, M., and Crick, D.C. (2009).**
463 Menaquinone synthesis is critical for maintaining mycobacterial viability during exponential
464 growth and recovery from non-replicating persistence. *Mol Microbiol* **72**, 85-97.
- 465 **Drapal, M., Perez-Fons, L., Wheeler, P.R., and Fraser, P.D. (2014).** The application of metabolite
466 profiling to Mycobacterium spp.: determination of metabolite changes associated with
467 growth. *J Microbiol Methods* **106**, 23-32.
- 468 **Eoh, H., and Rhee, K.Y. (2013).** Multifunctional essentiality of succinate metabolism in adaptation to
469 hypoxia in Mycobacterium tuberculosis. *Proc Natl Acad Sci U S A* **110**, 6554-6559.
- 470 **Gago, G., Diacovich, L., Arabolaza, A., Tsai, S.C., and Gramajo, H. (2011).** Fatty acid biosynthesis in
471 actinomycetes. *FEMS Microbiol Rev* **35**, 475-497.
- 472 **Garton, N.J., Christensen, H., Minnikin, D.E., Adegbola, R.A., and Barer, M.R. (2002).** Intracellular
473 lipophilic inclusions of mycobacteria in vitro and in sputum. *Microbiology* **148**, 2951-2958.

474 **Hampshire, T., Soneji, S., Bacon, J., James, B.W., Hinds, J., Laing, K., Stabler, R.A., Marsh, P.D., and**
475 **Butcher, P.D. (2004).** Stationary phase gene expression of *Mycobacterium tuberculosis*
476 following a progressive nutrient depletion: a model for persistent organisms? *Tuberculosis*
477 **84**, 228-238.

478 **Harrigan, G.G., and Goodacre, R. (2003).** Introduction. In *Metabolic profiling - Its Role in Biomarker*
479 *Discovery and Gene Function Analysis*, Vol., p.^pp. 1-9. Kluwer Academic Publishers, Edited
480 by Harrigan, G.G., and Goodacre, R. (ed.),^(eds.), United States of America.

481 **Harth, G., and Horwitz, M.A. (1999).** An inhibitor of exported *Mycobacterium tuberculosis*
482 glutamine synthetase selectively blocks the growth of pathogenic mycobacteria in axenic
483 culture and in human monocytes: extracellular proteins as potential novel drug targets. *J Exp*
484 *Med* **189**, 1425-1436.

485 **Jones, M.O., Perez-Fons, L., Robertson, F.P., Bramley, P.M., and Fraser, P.D. (2013).** Functional
486 characterization of long-chain prenyl diphosphate synthases from tomato. *Biochem J* **449**,
487 729-740.

488 **Kanehisa, M., Goto, S., Hattori, M., Aoki-Kinoshita, K.F., Itoh, M., Kawashima, S., Katayama, T.,**
489 **Araki, M., and Hirakawa, M. (2006).** From genomics to chemical genomics: new
490 developments in KEGG. *Nucleic Acids Res* **34**, D354-357.

491 **Lee, P.C., Salomon, C., Mijts, B., and Schmidt-Dannert, C. (2008).** Biosynthesis of ubiquinone
492 compounds with conjugated prenyl side chains. *Appl Environ Microbiol* **74**, 6908-6917.

493 **Low, K.L., Rao, P.S., Shui, G., Bendt, A.K., Pethe, K., Dick, T., and Wenk, M.R. (2009).** Triacylglycerol
494 utilization is required for regrowth of in vitro hypoxic nonreplicating *Mycobacterium bovis*
495 bacillus Calmette-Guerin. *Journal of bacteriology* **191**, 5037-5043.

496 **Mathew, R., Kruthiventi, A.K., Prasad, J.V., Kumar, S.P., Srinu, G., and Chatterji, D. (2010).**
497 Inhibition of mycobacterial growth by plumbagin derivatives. *Chem Biol Drug Des* **76**, 34-42.

498 **Mora, L., Bramley, P.M., and Fraser, P.D. (2013).** Development and optimisation of a label-free
499 quantitative proteomic procedure and its application in the assessment of genetically
500 modified tomato fruit. *Proteomics* **13**, 2016-2030.

501 **Nogueira, M., Mora, L., Enfissi, E.M., Bramley, P.M., and Fraser, P.D. (2013).** Subchromoplast
502 sequestration of carotenoids affects regulatory mechanisms in tomato lines expressing
503 different carotenoid gene combinations. *Plant Cell* **25**, 4560-4579.

504 **Rafidinarivo, E., Lanéelle, M.A., Montrozier, H., Valero-Guillén, P., Astola, J., Luquin, M., Promé,**
505 **J.C., and Daffé, M. (2009).** Trafficking pathways of mycolic acids: structures, origin,
506 mechanism of formation, and storage form of mycobacteric acids. *J Lipid Res* **50**, 477-490.

507 **Robertson, F.P., Koistinen, P.K., Gerrish, C., Halket, J.M., Patel, R.K., Fraser, P.D., and Bramley,**
508 **P.M. (2012).** Proteome changes in tomato lines transformed with phytoene synthase-1 in
509 the sense and antisense orientations. *J Exp Bot* **63**, 6035-6043.

510 **Russell, D.G., VanderVen, B.C., Lee, W., Abramovitch, R.B., Kim, M.J., Homolka, S., Niemann, S.,**
511 **and Rohde, K.H. (2010).** *Mycobacterium tuberculosis* wears what it eats. *Cell Host Microbe*
512 **8**, 68-76.

513 **Sassetti, C.M., Boyd, D.H., and Rubin, E.J. (2003).** Genes required for mycobacterial growth defined
514 by high density mutagenesis. *Mol Microbiol* **48**, 77-84.

515 **Sassetti, C.M., and Rubin, E.J. (2003).** Genetic requirements for mycobacterial survival during
516 infection. *Proc Natl Acad Sci U S A* **100**, 12989-12994.

517 **Selishcheva, A.A., Sorokoumova, G.M., and Nazarova, E.V. (2012).** Lipid Surrounding of
518 *Mycobacteria*: Lethal and Resuscitating Effects In *Understanding Tuberculosis - Deciphering*
519 *the Secret Life of the Bacilli*, Vol., p.^pp. 239-256. InTech, Edited by Cardona, P.-J.

520 **Shi, L., Sohaskey, C.D., Pfeiffer, C., Datta, P., Parks, M., McFadden, J., North, R.J., and Gennaro,**
521 **M.L. (2010).** Carbon flux rerouting during *Mycobacterium tuberculosis* growth arrest. *Mol*
522 *Microbiol* **78**, 1199-1215.

523 **Singhal, A., Arora, G., Sajid, A., Maji, A., Bhat, A., Virmani, R., Upadhyay, S., Nandicoori, V.K.,**
524 **Sengupta, S., and Singh, Y. (2013).** Regulation of homocysteine metabolism by
525 *Mycobacterium tuberculosis* S-adenosylhomocysteine hydrolase. *Sci Rep* **3**, 2264.
526 **Smeulders, M.J., Keer, J., Speight, R.A., and Williams, H.D. (1999).** Adaptation of *Mycobacterium*
527 *smegmatis* to stationary phase. *Journal of bacteriology* **181**, 270-283.
528 **Stehr, M., Elamin, A.A., and Singh, M. (2013).** Lipid inclusions in mycobacterial infections. In
529 Mahboub, B. (ed.), *Tuberculosis - Current Issues in Diagnosis and Management*. INTECH.
530 **Venkatesh, J., Kumar, P., Krishna, P.S., Manjunath, R., and Varshney, U. (2003).** Importance of
531 uracil DNA glycosylase in *Pseudomonas aeruginosa* and *Mycobacterium smegmatis*, G+C-rich
532 bacteria, in mutation prevention, tolerance to acidified nitrite, and endurance in mouse
533 macrophages. *The Journal of biological chemistry* **278**, 24350-24358.
534 **Walker, R.W., Barakat, H., and Hung, J.G. (1970).** The positional distribution of fatty acids in the
535 phospholipids and triglycerides of *Mycobacterium smegmatis* and *M. bovis* BCG. *Lipids* **5**,
536 684-691.
537 **Wang, R., Prince, J.T., and Marcotte, E.M. (2005).** Mass spectrometry of the *M. smegmatis*
538 proteome: protein expression levels correlate with function, operons, and codon bias.
539 *Genome Res* **15**, 1118-1126.
540 **Wayne, L.G., and Hayes, L.G. (1996).** An in vitro model for sequential study of shiftdown of
541 *Mycobacterium tuberculosis* through two stages of nonreplicating persistence. *Infect Immun*
542 **64**, 2062-2069.
543 **Wayne, L.G., and Sohaskey, C.D. (2001).** Nonreplicating persistence of mycobacterium tuberculosis.
544 *Annual review of microbiology* **55**, 139-163.
545 **Zeng, L., Shi, T., Zhao, Q., and Xie, J. (2013).** *Mycobacterium* sulfur metabolism and implications for
546 novel drug targets. *Cell Biochem Biophys* **65**, 77-83.

547

548

549 **SUPPORTING INFORMATION**

550 Supplementary File 1 – OD and cfu values of all growth conditions and mycobacteria

551 Supplementary File 2 - Average ratios and P-values of all growth conditions and mycobacteria

552

553 **FIGURE LEGENDS**

554 **Fig. 1.** Growth curves of *M. smegmatis* (a) and *M. bovis* BCG (b) under aerated and hypoxic cultivation.
555 These are representative of all the mycobacteria studied, though the actual OD values and sampling
556 points (diamonds, crosses and circles) vary for each species tested is (see methods). For Phase I
557 measurements were taken from lag to stationary phase. The induction time of elongated, aerated
558 (Phase II) and hypoxic (Phase III) cultivation is indicated by an arrow.

559 **Fig. 2.** Heat map of metabolite levels measured from lag phase over log and stationary phase. *M.*
560 *smegmatis*, *M. phlei*, *M. bovis* BCG, *M. avium* and *M. intracellulare* were grown under aerated
561 conditions and sampled at lag, log and stationary phase. The reference point for metabolite levels was
562 lag phase. Metabolites were grouped in polar (nucleotides, amino acids, organic acids and saccharides)
563 and non-polar (fatty acids, glycerol, -esters, -phosphates and isoprenoids) extracts. Changes are
564 indicated as increase (green), no change (grey), decrease (red) and not detected (white) shown in the
565 legend. Results were means of five replicates.

566 **Fig. 3.** Heat map of metabolite levels measured over Phase II. *M. smegmatis*, *M. phlei*, *M. bovis* BCG,
567 *M. avium* and *M. intracellulare* were grown under aerated conditions throughout and sampled from log
568 phase onwards over 28d. The reference point for metabolite levels was the first sampling point at log
569 phase. Metabolites were grouped in polar (nucleotides, amino acids, organic acids and saccharides)
570 and non-polar (fatty acids, glycerol, -esters, -phosphates and isoprenoids) extracts. Changes are
571 indicated as increase (green), no change (grey), decrease (red) and not detected (white) shown in the
572 legend. Results were means of five replicates.

573 **Fig. 4.** Heat map of metabolite levels measured over Phase III. *M. smegmatis*, *M. phlei*, *M. bovis* BCG,
574 *M. avium* and *M. intracellulare*. Those mycobacteria were grown under hypoxic conditions from log
575 phase onwards and sampled over this period until 28d. The reference point for metabolite levels was
576 the first sampling point at log phase. Metabolites were grouped in polar (nucleotides, amino acids,
577 organic acids and saccharides) and non-polar (fatty acids, glycerol, -esters, -phosphates and
578 isoprenoids) extracts. Changes are indicated as increase (green), no change (grey), decrease (red) and
579 not detected (white) shown in the legend. Results were means of five replicates.

580 **Fig. 5** Lipid secretion of *M. smegmatis* under hypoxic cultivation. (a) The secretion layer occurred
581 after three to four days of hypoxic cultivation of *M. smegmatis*. The translucent secretion layer (arrow)
582 was collected and analysed with MALDI for metabolite composition. (b) An average MALDI spectrum is
583 presented.

584 **Fig. 6.** Schematic representation of metabolic processes of mycobacteria over Phase I, II and III.
585 Mycobacterial cells were schematically displayed for Phase I, II and III. Arrows represented the

586 transition from Phase I to Phase II or III with depletion (cross) of oxygen (O₂) and/or nutrients.
587 Intracellular metabolic processes were indicated with black arrows and utilisation of compound classes
588 for the cell wall (grey circle) with grey arrows. The same changes of compound classes for all
589 mycobacteria tested were highlighted as up- and down- regulated (green and red, respectively).

590

591

592

593

594

595

596

597

598

599